Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

969440

registered interest
date	07/09/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Thromboembolism
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the research conducted by the Health Service Journal, published on 8 May 2018, if he will make an estimate on the number of patients at risk of developing a venous thromboembolism as a result of the decline in assessments being undertaken.
tabling member constituency	Houghton and Sunderland South
tabling member printed	Bridget Phillipson
uin	171670
answer	answer is ministerial correction date of answer 12/09/2018 answer text <p>In the third quarter of 2017/18, England as a whole continued to achieve the 95% NHS Standard Contract threshold for venous thromboembolism (VTE) risk assessments. Of the 3.7 million admitted adult inpatients for whom data was reported in this collection, 3.5 million (95%) were risk assessed for VTE on admission.</p><p> </p><p>NHS Improvement is working with providers to ensure that they are meeting this target on a consistent basis and that any variation is reduced to ensure patients are kept safe.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 12/09/2018 16:40:26 answering member 4067 label Biography information for Steve Brine
tabling member	4046 label Biography information for Bridget Phillipson

969472

registered interest
date	07/09/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Radiotherapy
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 4 January 2018 to Question 147424 on Radiotherapy, when the postcode-level dataset which will enable the calculation of travel times to radiotherapy centres will be published.
tabling member constituency	Westmorland and Lonsdale
tabling member printed	Tim Farron
uin	171667
answer	answer is ministerial correction date of answer 12/09/2018 answer text <p>In June 2018, The National Cancer Registration and Analysis Service (NCRAS) published three reports relating to patient travel times and cancer, in response to the Independent Cancer Taskforce recommendation 27.</p><p> </p><p>The reports are available at the following link:</p><p> </p><p><a href="http://www.ncin.org.uk/cancer_type_and_topic_specific_work/topic_specific_work/travel_times" target="_blank">http://www.ncin.org.uk/cancer_type_and_topic_specific_work/topic_specific_work/travel_times</a></p><p> </p><p>The reports cover the following topics:</p><p>- Travel Times and Methodology summarises NCRAS’ investigations of several possible ways of calculating travel times;</p><p>- Travel Times and Cancer Survival is an overview of survival for the four most common cancers, relative to travel time to the nearest hospital with a relevant multidisciplinary team; and</p><p>- Travel Times and Cancer Treatment is a report on treatment with radiotherapy for localised prostate cancer, relative to travel time to a radiotherapy centre.</p><p> </p><p>Postcode-level data is potentially disclosive and is therefore not made routinely available. Such data may be made available to researchers who apply through Public Health England’s Office for Data Release, with a specific health-care related research question and appropriate research ethics permissions.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 12/09/2018 16:38:09 answering member 4067 label Biography information for Steve Brine
tabling member	1591 label Biography information for Tim Farron

969473

registered interest
date	07/09/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Radiotherapy
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, when he plans to publish the Government response to the consultation on allocating funds to radiotherapy services which closed on 24 January 2018.
tabling member constituency	Westmorland and Lonsdale
tabling member printed	Tim Farron
uin	171668
answer	answer is ministerial correction date of answer 12/09/2018 answer text <p>Following the consultation – ‘Modernising radiotherapy services in England’ – NHS England plan to publish a consultation report which outlines the feedback themes, alongside publication of the final radiotherapy service specification. The publication is currently expected to take place in autumn 2018.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 171669 question first answered 12/09/2018 16:39:21 answering member 4067 label Biography information for Steve Brine
tabling member	1591 label Biography information for Tim Farron

969477

registered interest
date	07/09/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Radiotherapy
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the oral contribution of the Parliamentary Under Secretary of State for Health and Social Care of 10 January 2018, Official Report, column 146WH, when he plans to (a) publish the findings of the consultation on making radiotherapy services more accessible and (b) assess data on travel times for such therapy.
tabling member constituency	Westmorland and Lonsdale
tabling member printed	Tim Farron
uin	171669
answer	answer is ministerial correction date of answer 12/09/2018 answer text <p>Following the consultation – ‘Modernising radiotherapy services in England’ – NHS England plan to publish a consultation report which outlines the feedback themes, alongside publication of the final radiotherapy service specification. The publication is currently expected to take place in autumn 2018.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 171668 question first answered 12/09/2018 16:39:21 answering member 4067 label Biography information for Steve Brine
tabling member	1591 label Biography information for Tim Farron

969526

registered interest
date	07/09/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Methadone
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what comparative assessment he has made of the rates of recovery from heroin addiction through methadone in the UK and other countries.
tabling member constituency	Oxford East
tabling member printed	Anneliese Dodds
uin	171730
answer	answer is ministerial correction date of answer 12/09/2018 answer text <p>No comparative assessment has been made of the rates of recovery from heroin addiction through methadone in the United Kingdom and other countries.</p><p> </p><p>There has been no estimate made of the general rate of methadone usage in the last three years.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 171731 question first answered 12/09/2018 16:35:51 answering member 4067 label Biography information for Steve Brine
tabling member	4657 label Biography information for Anneliese Dodds

969527

registered interest
date	07/09/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Methadone
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what estimate he has made of the rate of methadone usage in the last three years.
tabling member constituency	Oxford East
tabling member printed	Anneliese Dodds
uin	171731
answer	answer is ministerial correction date of answer 12/09/2018 answer text <p>No comparative assessment has been made of the rates of recovery from heroin addiction through methadone in the United Kingdom and other countries.</p><p> </p><p>There has been no estimate made of the general rate of methadone usage in the last three years.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 171730 question first answered 12/09/2018 16:35:51 answering member 4067 label Biography information for Steve Brine
tabling member	4657 label Biography information for Anneliese Dodds

967805

registered interest
date	04/09/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential effect of the UK leaving the EU on patient access to short-shelf life medicines.
tabling member constituency	Cambridge
tabling member printed	Daniel Zeichner
uin	170342
answer	answer is ministerial correction date of answer 12/09/2018 answer text <p>The Government has made significant progress in negotiations with the European Union and remains confident the United Kingdom will leave with a good deal for both sides. This deal will include ensuring patients in the UK have access to appropriate, safe, and cost effective medicines, including short shelf-life medicines.</p><p> </p><p>However, as a responsible Government, we continue to prepare proportionately for all scenarios, including the unlikely outcome that we leave the EU without any deal in March 2019. Therefore on 23 August 2018, the Department wrote to a number of pharmaceutical companies that supply medicines for National Health Service patients from, or via, the EU/European Economic Area (EEA), asking them to ensure that they have a minimum of six weeks additional supply in the UK, over and above their business as usual operational buffer stocks by 29 March 2019.</p><p> </p><p>For certain medicines with short shelf lives, which cannot be reasonably stockpiled, we are specifically asking that where these products are imported to the UK from the EU/EEA via road haulage and roll-on, roll-off sea, road and rail routes, suppliers ensure in advance plans to air freight these medicines to the UK. This will ensure that UK patients have the same access to these medicines as they currently do in unlikely event of the UK leaving the EU without a deal.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 12/09/2018 16:26:05 answering member 4067 label Biography information for Steve Brine
tabling member	4382 label Biography information for Daniel Zeichner

967806

registered interest
date	04/09/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pharmaceutical Price Regulation Scheme
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what estimate his Department has made of the total value of rebates to be paid under the Pharmaceutical Price Regulation Scheme 2014.
tabling member constituency	Cambridge
tabling member printed	Daniel Zeichner
uin	170343
answer	answer is ministerial correction date of answer 12/09/2018 answer text <p>The Department has received £2,328 million from members of the Pharmaceutical Price Regulation Scheme (PPRS), as of Q1 2018, in respect of PPRS payments made under the 2014 scheme. The estimated United Kingdom income from PPRS payments in 2018/19 is £470 million. Published aggregate information on sales reports and payments made under the scheme on a quarterly basis can be found on the Government’s website at the following link:</p><p> </p><p><a href="https://www.gov.uk/government/collections/pprs-quarterly-net-sales-and-payment-information" target="_blank">https://www.gov.uk/government/collections/pprs-quarterly-net-sales-and-payment-information</a></p><p> </p><p>The Department administers the scheme on behalf of all UK nations and PPRS payments that companies make under the scheme in respect of the UK are allocated to each of the four countries on an agreed basis each year. The Department ensures that all the income it receives from PPRS payments in England is reinvested in the National Health Service for patients’ benefit. The Department includes the expected PPRS payments in setting the NHS England allocations in advance of each year. NHS England is responsible for allocating the overall budget between clinical commissioning groups, specialised commissioning etc.</p><p> </p><p>Following normal Government accounting rules, there is no separately identified or ring-fenced funding stream associated with the PPRS payment. The Government is committed to improving access to clinically and cost-effective medicines including innovative new medicines and to optimise patient outcomes from these medicines.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 170344 170345 question first answered 12/09/2018 16:32:57 answering member 4067 label Biography information for Steve Brine
tabling member	4382 label Biography information for Daniel Zeichner

967807

registered interest
date	04/09/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pharmaceutical Price Regulation Scheme
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what information his Department holds on how money raised from rebates paid under the Pharmaceutical Price Regulation Scheme 2014 has been used; and if he will make a statement.
tabling member constituency	Cambridge
tabling member printed	Daniel Zeichner
uin	170344
answer	answer is ministerial correction date of answer 12/09/2018 answer text <p>The Department has received £2,328 million from members of the Pharmaceutical Price Regulation Scheme (PPRS), as of Q1 2018, in respect of PPRS payments made under the 2014 scheme. The estimated United Kingdom income from PPRS payments in 2018/19 is £470 million. Published aggregate information on sales reports and payments made under the scheme on a quarterly basis can be found on the Government’s website at the following link:</p><p> </p><p><a href="https://www.gov.uk/government/collections/pprs-quarterly-net-sales-and-payment-information" target="_blank">https://www.gov.uk/government/collections/pprs-quarterly-net-sales-and-payment-information</a></p><p> </p><p>The Department administers the scheme on behalf of all UK nations and PPRS payments that companies make under the scheme in respect of the UK are allocated to each of the four countries on an agreed basis each year. The Department ensures that all the income it receives from PPRS payments in England is reinvested in the National Health Service for patients’ benefit. The Department includes the expected PPRS payments in setting the NHS England allocations in advance of each year. NHS England is responsible for allocating the overall budget between clinical commissioning groups, specialised commissioning etc.</p><p> </p><p>Following normal Government accounting rules, there is no separately identified or ring-fenced funding stream associated with the PPRS payment. The Government is committed to improving access to clinically and cost-effective medicines including innovative new medicines and to optimise patient outcomes from these medicines.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 170343 170345 question first answered 12/09/2018 16:32:58 answering member 4067 label Biography information for Steve Brine
tabling member	4382 label Biography information for Daniel Zeichner

967808

registered interest
date	04/09/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pharmaceutical Price Regulation Scheme
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, for what reasons rebates paid by manufacturers under the Pharmaceutical Price Regulation Scheme 2014 are not ring-fenced for the use of medicines; and if he will make a statement.
tabling member constituency	Cambridge
tabling member printed	Daniel Zeichner
uin	170345
answer	answer is ministerial correction date of answer 12/09/2018 answer text <p>The Department has received £2,328 million from members of the Pharmaceutical Price Regulation Scheme (PPRS), as of Q1 2018, in respect of PPRS payments made under the 2014 scheme. The estimated United Kingdom income from PPRS payments in 2018/19 is £470 million. Published aggregate information on sales reports and payments made under the scheme on a quarterly basis can be found on the Government’s website at the following link:</p><p> </p><p><a href="https://www.gov.uk/government/collections/pprs-quarterly-net-sales-and-payment-information" target="_blank">https://www.gov.uk/government/collections/pprs-quarterly-net-sales-and-payment-information</a></p><p> </p><p>The Department administers the scheme on behalf of all UK nations and PPRS payments that companies make under the scheme in respect of the UK are allocated to each of the four countries on an agreed basis each year. The Department ensures that all the income it receives from PPRS payments in England is reinvested in the National Health Service for patients’ benefit. The Department includes the expected PPRS payments in setting the NHS England allocations in advance of each year. NHS England is responsible for allocating the overall budget between clinical commissioning groups, specialised commissioning etc.</p><p> </p><p>Following normal Government accounting rules, there is no separately identified or ring-fenced funding stream associated with the PPRS payment. The Government is committed to improving access to clinically and cost-effective medicines including innovative new medicines and to optimise patient outcomes from these medicines.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 170343 170344 question first answered 12/09/2018 16:32:58 answering member 4067 label Biography information for Steve Brine
tabling member	4382 label Biography information for Daniel Zeichner